Scott Johnson, President and CEO of The Myelin Repair Foundation has announced that patients are now being enrolled in a clinical trial conducted to study guanabenz, an FDA-approved drug to treat high blood pressure that was identified by MRF-funded researchers as a potential therapeutic to reduce loss of myelin, in multiple sclerosis (MS) patients.
http://www.bizjournals.com/sanfrancisco/morning_call/2015/05/guanabenz-myelin-repair-multiple-sclerosis-ms.html?page=all

http://www.myelinrepair.org/documents/Guanabenz_MRF-008_Press_Release_FINAL_04-30-2015.pdf


How a white powder couldn't pass U.S. Customs but could save MS patients - San Francisco...
www.bizjournals.com
The nonprofit Myelin Repair Foundation in Saratoga and the National Institutes of Health will take an out-of-production, generic high blood pressure treatment into a clinical trial in multiple sclerosis.